LuQi Biopharma and RuiTu Bio Secure Over RMB 100 Million in Recent Funding Rounds Amid Active Investment in China's Healthcare Sector

　　【Pharmaceutical Network Industry Dynamics】 Recently, CytosinLab Therapeutics, a clinical-stage biotechnology company focusing on the next generation of epigenetic treatment technologies, announced the completion of a nearly 100-million-yuan Series A+ round of financing. The funds from this round will mainly be used to accelerate the clinical development of multiple products by CytosinLab Therapeutics and continuously improve the company's EpigenPLUS epigenetic technology R&D platform.
 

According to the review, the investment and financing activities in China's medical and health sector remained relatively active last week (December 18th ~ December 22nd), with no less than eight enterprises receiving investments. Among them, Novamab and reetoo obtained financing of over 100 million RMB.
 

On December 18, Novamab successfully completed a Series B financing round of over 100 million RMB. This round was led by Shanghai Shengdi Private Fund Management Co., Ltd., with existing shareholder Chengdu BioCity Fund (Guosheng Capital) increasing its investment. Oriental Gaosheng and Bocom International served as financial advisors for this round. The funds will be used for Phase II clinical research of two inhaled antibody drugs (LQ036, LQ043) independently developed by the company based on its "Inhaled Large Molecule Drug Development Platform," and to further expand the team and replenish corporate working capital.
 

On December 18, reetoo announced the successful completion of a B2 round of financing exceeding 100 million yuan. This round of financing was led by Guoke Investment and a well-known fund in China, with participation from Shentou Control Capital, and Dian Shi Capital serving as the exclusive financial advisor. The funds will mainly be used for the production, commercialization, and R&D iteration of core products. Data shows that reetoo is an artificial intelligence medical device developer, with a product portfolio covering multiple testing scenarios such as blood, body fluids, tissues, and sputum.
 

Moreover, on December 19, HemaCell announced the completion of the first closing of its Series A1 financing round, with the second closing simultaneously initiated, expected to conclude in three months. The funds raised will primarily be used to advance HemaCell's three platelet-related pipeline IND applications, support the completion of various aspects of preclinical research, and simultaneously promote the industrialization of multiple sectors such as platelet drug delivery and platelet lysate.
 

On December 19, Tanjian Future announced the completion of a multi-million yuan Series A financing round. The proceeds from this round will be used to accelerate the construction of a digital and intelligent innovative industrial service system, expand the market, and build a professional service team. Data shows that Tanjian Future is a one-stop life science innovation industrial service platform that relies on big data and artificial intelligence technology to provide diversified services such as financing and mergers and acquisitions, industrial consulting, and operations for medical innovation enterprises, as well as government and industrial departments.
 

On December 18, Bonacia Pharma announced the completion of a multi-million RMB B-round financing. This funding will help the company advance its internationalization and digital intelligence operations, further expanding into the North American and Southeast Asian markets. On December 18, Yirui Pharma announced the completion of its A+ round of financing. The funds raised will be used to accelerate the U.S. Phase II clinical trial of the innovative drug YR-001 for the treatment of autoimmune skin diseases, as well as for the preclinical and early clinical development of other projects within the company. On December 18, Zhejiang Weiyi Biotechnology Co., Ltd. completed a 10-million RMB angel round of financing, which will be used to strengthen the company's R&D capabilities, advance product development, and promote market expansion. On December 18, Beijing Zhongke Microbio completed a multi-million RMB Pre-A round of financing. This round of funding will support Zhongke Microbio in intensifying market promotion, brand building, and clinical research, developing more beneficial microorganisms for human health.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.